Celltrion Reports Results of CT-P59 in P-I Study for COVID-19

Share this

Celltrion Reports Results of CT-P59 in P-I Study for COVID-19


  • The P-I clinical trial involves assessing CT-P59 (20/40/80 mg/kg) vs PBO in 18 patients with mild symptoms of SARS-COV-2 infection who were randomized into 3 cohorts
  • Results: patients demonstrated a 44% reduction in mean clinical recovery time- while no patients required hospitalization or antiviral therapy
  • Celltrion has submitted the IND application for the clinical trial globally & plans to conduct global P-II & P-III trials including Korea. Additionally- Celltrion has also initiated a post-exposure prophylaxis study assessing CT-P59 as a protective treatment- by investigating the efficacy of the treatment in those who have been in contact with confirmed SARS-CoV-2 infected patients

 ­ Ref: Businesswire | Image: Celltrion

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions